Management of Gestational Trophoblast Disease: An Integrative Review of National and International Guidelines

Abstract

GTD (Gestational Trophoblastic Disease) is a pathology that encompasses benign and malignant clinical forms, affects women of childbearing age, has a variable incidence and is more frequent in developing or underdeveloped countries, colliding with the economic barrier. The frequent absence of clear protocols and guidelines for the correct diagnosis and treatment of the aforementioned pathology results in inadequate risk classification, imprecise treatment and failed post-therapeutic observation, increasing the risk of relapses, morbidity and mortality. The present study aims to compare the different national and international guidelines in the management of GTD, through an integrative review. Nine articles were selected and it was observed that the main international reference centers are agreed with the management suggested by the IFGO (International Federation of Gynecology and Obstetrics), being the conduct in the Hydatidiform Mole (HM): evacuation by suction and curettage under ultrasound guidance, followed by hCG monitoring every 1 -2 weeks until normalized; in low-risk GTN (Gestational Trophoblastic Neoplasm

Hydatidiform Mole—Between Chromosomal Abnormality, Uniparental Disomy and Monogenic Variants: A Narrative Review

“…The benign form of GTD is represented by a hydatidiform mole (HM), which is the most common. The malignant forms of GTD are represented by trophoblastic tumors (with two forms-epithelial trophoblastic and placental site trophoblastic tumors), choriocarcinoma and invasive moles [1].…”